Taifu Capital
VC Fund
Shanghai, China
Taifu Capital is a venture capital firm that invests in medical technology and pharmaceutical companies in early stages of development.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 22%
Last updated:
For AI agents: llms.txt
Industries Taifu Capital invests in
Stages Taifu Capital invests in
Countries Taifu Capital invests in
Investment Focus
Industry
- Health Care 4 (44%)
- Biotechnology 4 (44%)
- Medical 3 (33%)
- Pharmaceutical 2 (22%)
- Biopharma 1 (11%)
Stage
- Series A 3 (33%)
- Series B 3 (33%)
- Angel 2 (22%)
- Seed 1 (11%)
Country
- China 4 (44%)
- United States 3 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Taichu Biotechnology
|
Taichu Biotechnology offers customized CRO+CDMO technical services for single and combined business sectors for the development and manufacturing of various novel pharmaceuticals. | Angel / Jul 01, 2022 | |
|
Sanegene Bio
|
Sanegene Bio is currently operating in stealth mode. | $38M / Series A / Sep 01, 2021 | |
NuProbe
|
An early stage molecular diagnostics company. | $42M / Series B / Jan 11, 2021 | |
BioNova Pharma
|
Biopharma company for cancer medicine | $25M / Series B / Oct 20, 2020 | |
Exegenesis Bio
|
Exegenesis is going to develop new medicine based on gene therapy and focuses on China and the global market. The team consists of experienced professionals, including gene therapy drug design, preclinical studies and clinical development. | Seed / Aug 03, 2020 | |
|
Exegenesis Bio
|
Exegenesis is going to develop new medicine based on gene therapy and focuses on China and the global market. The team consists of experienced professionals, including gene therapy drug design, preclinical studies and clinical development. | Series B / Aug 03, 2020 | |
LaNova Medicines
|
LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs. | Series A / Jul 01, 2020 | |
Zion Pharma
|
Zion is a leading drug discovery platform that develops "me-better" drugs that address true unmet needs. | $11.6M / Series A / Jan 01, 2019 | |
|
Zion Pharma
|
Zion is a leading drug discovery platform that develops "me-better" drugs that address true unmet needs. | $2.6M / Angel / May 01, 2018 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Taifu Capital invest in?
Taifu Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 9 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Taifu Capital last invest?
The most recent investment recorded for Taifu Capital closed in Jul 2022. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
